Edgewise Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Edgewise Therapeutics, Inc. (EWTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are EWTX insiders buying or selling?
In the last 12 months, Edgewise Therapeutics, Inc. insiders reported 1 open-market purchase ($199.4K) and 12 sales ($19.5M) — net selling of $19.3M. Since March 2021, Trabud has recorded 90 Form 4 filings for EWTX: 16 buys ($79.0M) and 74 sells ($46.5M).
Source: SEC EDGAR Form 4
Key Statistics (March 2021 – Aug 14, 2026)
Total Form 4 filings
90
SEC EDGAR
Insider filers
14
Insider buys (16)
$79.0M
Insider sells (74)
$46.5M
Insider sentiment
Net buyingNet insider flow of $32.6M in net buying since March 2021, and $19.3M in net selling over the last 12 months.
Recent EWTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Joanne M. Donovan | CMO | Sale | 9.4K | $43.71 | $412.7K | SEC ↗ |
| Aug 14, 2026 | Alan J Russell | Chief Scientific Officer | Sale | 5.9K | $43.73 | $258.0K | SEC ↗ |
| Aug 14, 2026 | John R Moore | General Counsel | Sale | 5.0K | $43.82 | $219.8K | SEC ↗ |
| Aug 14, 2026 | Behrad Derakhshan | Chief Business Officer | Sale | 5.1K | $43.81 | $223.4K | SEC ↗ |
| Aug 14, 2026 | Kevin Koch | President and CEO | Sale | 18.0K | $43.68 | $785.0K | SEC ↗ |
| Jul 2, 2026 | Alan J Russell | Chief Scientific Officer | Sale | 200.0K | $39.41 | $7.9M | SEC ↗ |
| May 5, 2026 | Joanne M. Donovan | CMO | Sale | 55.2K | $37.88 | $2.1M | SEC ↗ |
| Apr 2, 2026 | Joanne M. Donovan | CMO | Sale | 28.7K | $32.31 | $926.1K | SEC ↗ |
| Mar 31, 2026 | Joanne M. Donovan | CMO | Sale | 21.3K | $32.12 | $685.3K | SEC ↗ |
| Mar 30, 2026 | Joanne M. Donovan | CMO | Sale | 16.4K | $30.98 | $506.7K | SEC ↗ |
| Jan 23, 2026 | Badreddin Edris | Director | Sale | 115.5K | $29.44 | $3.4M | SEC ↗ |
| Nov 13, 2025 | Alan J Russell | Chief Scientific Officer | Sale | 100.0K | $21.12 | $2.1M | SEC ↗ |
| Nov 13, 2025 | Jonathan C Fox | Director | Purchase | 10.7K | $18.64 | $199.4K | SEC ↗ |
| Aug 28, 2025 | Alan J Russell | Chief Scientific Officer | Sale | 100.0K | $14.60 | $1.5M | SEC ↗ |
| Aug 14, 2025 | John R Moore | General Counsel | Sale | 2.1K | $13.39 | $28.1K | SEC ↗ |
| Aug 14, 2025 | Behrad Derakhshan | Chief Business Officer | Sale | 2.5K | $13.39 | $33.4K | SEC ↗ |
| Aug 14, 2025 | Michael R Carruthers | Chief Financial Officer | Sale | 1.4K | $13.39 | $19.1K | SEC ↗ |
| Aug 14, 2025 | Alan J Russell | Chief Scientific Officer | Sale | 1.9K | $13.39 | $25.5K | SEC ↗ |
| Aug 14, 2025 | Kevin Koch | President and CEO | Sale | 8.0K | $13.39 | $106.8K | SEC ↗ |
| Aug 14, 2025 | Joanne M. Donovan | CMO | Sale | 2.9K | $13.39 | $38.3K | SEC ↗ |
| May 8, 2025 | Alan J Russell | Chief Scientific Officer | Sale | 1.6K | $16.45 | $25.5K | SEC ↗ |
| May 8, 2025 | John R Moore | General Counsel | Sale | 1.9K | $16.45 | $31.8K | SEC ↗ |
| May 8, 2025 | Kevin Koch | President and CEO | Sale | 4.3K | $16.45 | $70.4K | SEC ↗ |
| May 8, 2025 | Joanne M. Donovan | CMO | Sale | 5.2K | $16.45 | $85.3K | SEC ↗ |
| May 8, 2025 | Behrad Derakhshan | Chief Business Officer | Sale | 1.7K | $16.45 | $27.8K | SEC ↗ |
Showing the 25 most recent of 90 Form 4 filings for Edgewise Therapeutics, Inc..
Most active EWTX insiders
- Alan J Russell23 filings
- John R Moore17 filings
- Joanne M. Donovan11 filings
- Behrad Derakhshan8 filings
- Kevin Koch7 filings
Ask anything about EWTX insider activity
Use Trabud's AI agent to query Edgewise Therapeutics, Inc.'s Form 4 history in plain English — "Show me EWTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentEWTX insider trading FAQ
Are Edgewise Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Edgewise Therapeutics, Inc. insiders reported 1 open-market purchase ($199.4K) and 12 sales ($19.5M) — net selling of $19.3M. Since March 2021, Trabud has recorded 90 Form 4 filings for EWTX: 16 buys ($79.0M) and 74 sells ($46.5M). Over the full record that is net buying of $32.6M.
How many insiders trade EWTX stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Edgewise Therapeutics, Inc.. The most recent filing was accepted on Aug 14, 2026.
Where does Trabud get EWTX insider trading data?
All EWTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.